Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

Investigational CAR T-Cell Therapy Improves Objective Response Rate in Patients With Aggressive NHL

At the 2017 AACR Annual Meeting, Frederick L. Locke, MD, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and...

Investigational Drug TEW-7197 Improves Myeloma Outcomes Both as Single Agent and in Combination With...

TGF-β, a multifunctional cytokine, is produced in multiple myeloma (MM) cells and cells in the bone marrow (BM) tumor microenvironment (TME), where it also...

BION-1301 May Improve Survival and Inhibit Treatment Resistance for Patients With Myeloma

In a preclinical study presented at the 2017 AACR Annual Meeting, BION-1301, an anti-human APRIL blocking antibody, inhibited the survival of multiple myeloma (MM)...

CHRONOS-1: Copanlisib Shows Promise for Patients With Relapsed/Refractory Indolent B-Cell NHL

Patients with relapsed/refractory indolent B-cell lymphomas often have limited options beyond standard therapies once their disease progresses. Copanlisib, an intravenously administered pan-class I phosphatidylinositol...

A Tale of Two Proteasome Inhibitors: Carfilzomib Versus Bortezomib in Multiple Myeloma

At the 16th International Myeloma Workshop (IMW), two clinical trials of patients with newly diagnosed and relapsed/refractory multiple myeloma (NDMM; RRMM) showed disparate results....

Denosumab Delays Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

Denosumab (a monoclonal antibody that targets the RANK ligand) was noninferior to zoledronic acid (ZA) in delaying the time to a first skeletal-related event...

The Multiple Myeloma Genome Project: Developing a Risk Stratification System for Multiple Myeloma

An update from the Multiple Myeloma Genome Project (MMGP), presented at the 16th International Myeloma Workshop (IMW), revealed several associations between the development of...

CPX-351 Extends Overall Survival Over 7+3 in Older Patients With Secondary Acute Myeloid Leukemia

CHICAGO--CPX-351, a liposomal formulation of cytarabine and daunorubicin, improved overall survival compared with a standard 7+3 regimen of cytarabine and daunorubicin in older patients...

Birinapant Plus Azacitidine Not Superior to Azacitidine Alone in Myelodysplastic Syndrome

CHICAGO--Adding the investigational agent birinapant to azacitidine did not improve outcomes, compared with azacitidine alone, in patients with myelodysplastic syndrome (MDS), according to results...

Erythropoiesis-Stimulating Agents and the Risk of Thrombosis in Cancer-Associated Anemia

CHICAGO--Patients with cancer are at risk for developing anemia. The treatment of cancer-associated anemia remains a challenge, given that the most effective therapy for...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.